0001217234-25-000046
SEC filingRevenue declined 6% YoY to $86.7M due to negative prior-period adjustments, while testing volume grew 13%.
For Q2 2025, total revenue declined 6% YoY to $86.7 million, driven by a 13% drop in testing services revenue to $62.0 million. The decline was primarily due to negative prior-period revenue adjustments of $3.8 million under ASC 606; excluding these adjustments, testing services revenue grew 14% on higher volume. Product revenue rose 12% to $11.8 million, and patient and digital solutions revenue increased 19% to $12.8 million. Gross margin contracted to 67.1% from 69.6% due to a higher mix of lower-margin patient solutions and cost increases in testing and digital. Net loss widened to $8.6 million from $4.6 million, reflecting higher sales and marketing expenses (up 16% to $24.3 million) and litigation settlement costs of $0.4 million, partially offset by lower R&D and G&A expenses.
Testing services volume grew 13% YoY to 49,500 reports, but revenue per test declined due to payer mix and prior-period adjustments. The company highlighted ongoing efficiency measures to lower laboratory costs. Product segment benefited from strong adoption of NGS-based kitted solutions. Patient and digital solutions revenue growth was broad-based, led by Ottr software and transplant pharmacy sales. Cost trends varied: testing and digital costs rose with volume, while product cost declined 21% on manufacturing efficiencies and favorable supplier pricing.
Management did not provide quantitative guidance but expressed confidence that existing cash ($186.3 million) and expected operating cash flows will fund operations for at least 12 months. The company noted a new $50 million share repurchase program authorized in May 2025. Key strategic priorities include expanding testing volume, investing in R&D for new products (AlloCell, additional transplant solutions), and growing the patient and digital solutions portfolio. Near-term headwinds include ongoing revenue adjustment volatility and competitive pressures in transplant diagnostics.
As of June 30, 2025, CareDx holds $68.2 million in cash and cash equivalents and $118.0 million in marketable securities, totaling $186.2 million in liquid assets. Total assets are $444.3 million, with stockholders' equity of $327.4 million. The company carries no debt, with total liabilities of $116.9 million consisting primarily of operating lease liabilities ($29.1 million), accrued compensation, and litigation settlement accruals.
CareDx has $33.6 million in future operating lease payments through 2033, with $4.0 million due in the remainder of 2025, $16.1 million in 2026-2028, and $13.5 million thereafter. Additionally, royalty commitments exist under license agreements with Illumina (mid-single to low-double digits on covered product sales) and a university (low single digits), but no specific dollar amounts are disclosed. A litigation settlement obligation of $20.25 million is accrued as of June 30, 2025, offset by $14.9 million in expected insurance proceeds.
During the six months ended June 30, 2025, CareDx repurchased 3.0 million shares for $50.0 million under the February 2025 Repurchase Program, completing that program. On May 30, 2025, the Board authorized a new $50.0 million repurchase program, with the full amount remaining available at quarter-end. No dividends were paid. Capital expenditures totaled $2.6 million for the six months, funded by operating cash flows.
The company operates as a single reportable segment. For the six months ended June 30, 2025, total revenue of $171.4 million was generated 94.2% in the United States ($161.5 million) and 5.8% from Rest of World ($9.9 million). Revenue by service line included testing services ($124.0 million), product revenue ($22.6 million), and patient & digital solutions ($24.8 million).